Corbus Pharmaceuticals Holdings, Inc.
CRBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595097
In the last 90 days, Corbus Pharmaceuticals Holdings, Inc. insiders filed 1 open-market purchase and 3 sales; 107 institutions reported holding it in 13F filings for Q2 2026, worth $129.1M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Corbus Pharmaceuticals Holdings, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 71 | 1 | 65 | −5 |
| Shares | 31.8M | 2.65K | 23.4M | −8.45M (−26.5%) |
| Value | $8.04M | $668 | $3.86M | −$4.18M (−52.0%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Corbus Pharmaceuticals Holdings, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ExodusPoint Capital Management, LP | 362,544 | $60.0K | 0.00% |
| Kingsbury Capital Investment Advisors LLC | 33,700 | $6.00K | 0.01% |
| Two Sigma Advisers, LP | 16,800 | $3.00K | 0.00% |
| ARS Wealth Advisors Group, LLC | 10,000 | $2.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 7,395 | $1.00K | 0.00% |
| Massmutual Trust Co FSB | 500 | $0 | 0.00% |
| Activest Wealth Management | 1,120 | $0 | 0.00% |
Sold out (12)
Institutions that held Corbus Pharmaceuticals Holdings, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Davy Global Fund Management Ltd | 457,209 | $115.0K |
| Vident Investment Advisory, LLC | 267,612 | $67.0K |
| Jane Street Group, LLC | 83,409 | $21.0K |
| Citadel Advisors LLC | 68,957 | $17.0K |
| Two Sigma Securities, LLC | 38,273 | $10.0K |
| Envestnet Asset Management Inc | 35,518 | $9.00K |
| Platform Technology Partners | 33,750 | $9.00K |
| HRT Financial LP | 26,309 | $6.00K |
| Spire Wealth Management | 2,018 | $1.00K |
| Captrust Financial Advisors | 750 | $0 |
| Rockefeller Capital Management L.P. | 510 | $0 |
| CoreCap Advisors, LLC | 750 | $0 |
Not filed for Q3 2022 yet (1)
Institutions that held Corbus Pharmaceuticals Holdings, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Exane Derivatives | 2,650 | $668 |